Skip to main navigation
Skip to search
Skip to main content
Universidad del Rosario Home
English
Español
Home
Profiles
Research units
Research output
Projects
Press/Media
Datasets
Prizes
Activities
Impacts
Student theses
Search by expertise, name or affiliation
Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
Juan Camilo Sarmiento-Monroy
, Luisa Parada-Arias
, Milena Rodríguez-López
,
Mónica Rodríguez-Jiménez
,
Nicolás Molano-González
, Adriana Rojas-Villarraga
, Rubén Darío Mantilla
Center for Autoimmune Diseases Research (CREA)
urosario
Research output
:
Contribution to Journal
›
Review article
›
peer-review
4
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Subcutaneous abatacept in rheumatoid arthritis: A real-life experience'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
2-median
12%
Abatacept
100%
ACR Criteria
12%
Activity Function
12%
Activity Impairment
12%
Adverse Events
12%
Anti-cyclic Citrullinated Peptide Antibody (anti-CCP)
50%
Antibody Concentration
25%
Baseline Characteristics
12%
Biologic DMARDs
12%
Colombia
12%
Concomitant Use
12%
Constitutional Symptoms
12%
Cox Proportional Hazards Regression Model
25%
Curve-based
12%
Demographic Characteristics
12%
Disease Activity
12%
Disease Activity Score 28 (DAS28)
37%
Disease Duration
12%
Disease Pattern
12%
Drug Survival
37%
Drug Suspension
12%
Erosive Disease
12%
Female Gender
12%
Functional Impairment
12%
Good Safety
12%
Headache
12%
Lack of Response
12%
Linear Mixed Model
12%
Loss of Effectiveness
12%
Low Activity
12%
Median Time
12%
Methotrexate
12%
Monotherapy
12%
Nave
12%
Outpatient Center
12%
Patient Characteristics
12%
Physical Function
12%
Published Data
12%
R Software
12%
RAPID3
50%
Real-world Experience
100%
Retention Rate
12%
Retrospective Cohort Study
12%
Rheumatoid Arthritis
100%
Rheumatoid Arthritis Patients
12%
Rheumatoid Factor
25%
Rheumatologic Diseases
12%
Rheumatology
25%
Route of Administration
12%
Safety Profile
12%
Seropositivity
12%
Statistical Analysis
12%
Statistical Significance
12%
Subcutaneous Administration
12%
Survival Curve
25%
Time-to-treatment
12%
Medicine and Dentistry
Abatacept
100%
Adverse Event
12%
Anti-Citrullinated Protein Antibody
50%
Constitutional Symptoms
12%
DAS28
37%
Disease Activity
12%
Disease Duration
12%
Disease-Modifying Antirheumatic Drug
12%
Diseases
25%
Functional Disease
12%
Headache
12%
Infection
12%
Inflammatory Arthritis
100%
Methotrexate
12%
Monotherapy
12%
Outpatient
12%
Personal Experience
100%
Proportional Hazards Model
25%
Retrospective Cohort Study
12%
Rheumatoid Arthritis
100%
Rheumatoid Factor
25%
Rheumatology
25%
Routine Assessment of Patient Index Data
50%
Subcutaneous Injection
12%
Pharmacology, Toxicology and Pharmaceutical Science
Abatacept
100%
Adverse Event
12%
Cohort Study
12%
Cyclic Citrullinated Peptide Antibody
50%
Disease Activity
12%
Disease Duration
12%
Diseases
25%
Functional Disease
12%
Headache
12%
Infection
12%
Inflammatory Arthritis
100%
Methotrexate
12%
Monotherapy
12%
Rheumatoid Arthritis
100%
Rheumatoid Factor
25%
Route of Administration
12%
Subcutaneous Injection
12%
Immunology and Microbiology
Abatacept
100%
Anti-Citrullinated Protein Antibody
50%
Antibody Blood Level
25%
Inflammatory Arthritis
100%
Methotrexate
12%
Personal Experience
100%
Rheumatoid Factor
25%
Seropositivity
12%
Neuroscience
Abatacept
100%
Cyclic Citrullinated Peptide Antibody
50%
Headache
12%
Methotrexate
12%
Rheumatoid Arthritis
100%
Rheumatoid Factor
25%
Rheumatology
25%